What the evidence supports: BPC-157 consistently improves tendon healing outcomes in animal models across multiple tissue types and injury models TB-500 accelerates wound healing and tissue repair in preclinical studies with measurable improvements in re-epithelialization, collagen deposition, and angiogenesis GHK-Cu enhances collagen synthesis and modulates thousands of genes involved in tissue repair GHRP-2 shifts macrophage polarization favorably in a rotator cuff tear model Relaxin-2 eliminates capsular fibrosis in a frozen shoulder mouse model No significant toxicity has been identified in preclinical BPC-157 studies What remains uncertain: Whether animal study results translate to equivalent human outcomes for shoulder conditions specifically Optimal dosing for human shoulder injuries (all protocols are extrapolated from animal data and clinical observation) Long-term safety with repeated use Whether peptides meaningfully reduce rotator cuff retear rates after surgical repair in humans How peptide therapy compares to established treatments like PRP in controlled human studies Potential interactions with medications commonly used by shoulder pain patients What we need: Randomized controlled trials of BPC-157 and TB-500 for specific shoulder conditions in humans Head-to-head comparisons of peptide therapy versus established treatments Long-term safety data from monitored human use Standardized dosing protocols based on human pharmacokinetic data Studies combining peptides with rehabilitation to assess synergistic effects The preclinical evidence is compelling
Pathological causes of elevated B12 warrant careful consideration: Haematological disorders : Myeloproliferative neoplasms (polycythaemia vera, chronic myeloid leukaemia), acute leukaemia, and lymphoproliferative disorders can increase B12-binding proteins (transcobalamin and haptocorrin), elevating total serum B12 [3] Liver disease : Hepatocellular damage releases stored B12 into circulation
The same 2005 trial also examined a combination of 5% Leuphasyl and 5% Argireline applied over 28 days, resulting in an average wrinkle depth reduction of 24.62%, with maximum reductions observed up to 46.53% , indicating a synergistic effect between the two peptides
And the dosage shows .2ml how is that figured or is that equal to 20mg
Gastrointestinal effects Nausea is the most commonly reported side effect and typically peaks during dose escalation
